Peritoneal Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Platinum-resistant Ovarian Cancer Interventions:   Drug: Luveltamab tazevibulin;   Drug: Pegfilgrastim Sponsor:   Sutro Biopharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2023 Category: Research Source Type: clinical trials